ManNAc

Phase 2Small molecule

LLeadiant Biosciences, Inc.

ManNAc is one of 12 small molecule programs targeting Focal Segmental Glomerulosclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Focal Segmental GlomerulosclerosisRecruiting

Focal Segmental GlomerulosclerosisPhase 2

Recruiting

Competition

Competitive Landscape

13 competitors in Focal Segmental Glomerulosclerosis

#DrugCompanyPhaseTrials

Empaveli

Apellis Pharmaceuticals

Approved

—2

Accutane

CConrado Roberto Hoffmann Filho

Glucophage

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—5

Filspari

TTravere Therapeutics, Inc.

Phase 3

1 6

Wayrilz

GGenzyme, a Sanofi Company

Phase 2

1 7

Frexalimab

Sanofi

Phase 2

1 8

Brivekimig

Sanofi

Phase 2

1 9

Prograf

VVeloxis Pharmaceuticals

Preclinical

2 10

ManNAc

LLeadiant Biosciences, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Recruiting

Focal Segmental Glomerulosclerosis

NCT06664814

Clinical

Trials by Indication[1]

Myopathy3 trials

An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

Completed·NNational Human Genome Research Institute (NHGRI)·Phase 2·NCT02346461·12 enrolled

Multi-Center Study of ManNAc for GNE Myopathy

Active, not recruiting·LLeadiant Biosciences, Inc.·Phase 2·NCT04231266·54 enrolled

Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)

Completed·NNational Human Genome Research Institute (NHGRI)·Phase 1·NCT01634750·26 enrolled

Focal Segmental Glomerulosclerosis1 trial

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases

Recruiting·NNational Human Genome Research Institute (NHGRI)·Phase 2·NCT06664814·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ManNAc. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ManNAc compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ManNAc. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Leadiant Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLeadiant Biosciences, Inc.

ManNAc

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Myopathy3 trials

Focal Segmental Glomerulosclerosis1 trial

References

Drug Info

Quick Facts

Related News